Drug Profile
VS 105
Alternative Names: CK 15; VS-105Latest Information Update: 14 Sep 2023
Price :
$50
*
At a glance
- Originator Vidasym
- Developer Cinkate Pharmaceuticals; Vidasym
- Class Cardiovascular therapies; Osteoporosis therapies; Vitamin D analogues
- Mechanism of Action Calcitriol receptor modulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes - Osteoporosis; Renal failure
Highest Development Phases
- Phase I Renal failure
- Preclinical Osteoporosis
Most Recent Events
- 14 Sep 2023 VS 105 is still in phase I trial for Renal failure in USA (PO) (Vidasym pipeline, September 2023)
- 14 Sep 2023 VS 105 is still in preclinical trial for Osteoporosis in USA (PO) (Vidasym pipeline, September 2023)
- 14 Sep 2023 VS 105 is still in preclinica trial for Renal failure in China (PO) (Vidasym pipeline, September 2023)